masteron only cycle
Masteron only cycle mobilization can take place only in donors who meet the standard clinical and laboratory criteria for stem cell donation. Particular attention should be paid to haematological parameters and the presence of infectious diseases.
The safety and efficacy of the drug Tevagrastim from healthy donors aged 16 years and older than 60 years have not been studied.
Transient leukocytosis was observed in 41% of patients. Thrombocytopenia after administration of filgrastim and leukapheresis observed in 35% of donors. In addition, 2 cases of thrombocytopenia after leukapheresis procedure.
If required more than one conducting leukapheresis, particular care should be monitored every platelet count before apheresis procedure, particularly if the platelet count below L. Undergo leukapheresis not recommended if the platelet count less than , or when using anticoagulants are hemostatic disorders.
In healthy donors, who receive for mobilization , should regularly monitor all indicators of clinical blood test before their normalization. Monitoring the safety of the drug in healthy donors Tevagrastim continues. At the present time we can not exclude the risk of a malignant myeloid clone donors. Medical centers conducting apheresis procedure. it is recommended to carry out systematic monitoring of the state of the stem cell donors for at least 10 years in order to monitor the safety of Tevagrastim drug in the long term.
There is information about the private, mostly asymptomatic cases of splenomegaly and very rare cases of splenic rupture in healthy donors and patients following administration masteron only cycle. Some cases of splenic rupture were fatal. In this connection must be carefully controlled spleen size (clinical examination (palpation) and ultrasound). It is necessary to take into account the risk of splenic rupture in donors and patients when they develop pain in the upper left part of the abdomen or the upper part of the left shoulder.
The Post-registration period from healthy donors very rare cases of adverse effects of on the respiratory system (haemoptysis, pulmonary haemorrhage, pulmonary infiltrates, dyspnoea and hypoxia).If you suspect the presence of these symptoms should consider the feasibility of further use of the drug and the need for appropriate treatment.
Precautions to recipients of allogeneic obtained with filgrastim
When allogeneic risk of acute or chronic reaction “graft versus host” is higher than in allogeneic bone marrow transplantation.
Precautions for patients with masteron only cycle
The amount of blood cells
is necessary to carefully control the amount of platelets, especially during the first few weeks of treatment. If the patient develops thrombocytopenia (platelet count over time of less than 100 x 10 9 / l), should be considered a temporary lifting of the drug or reducing its dose.